EULAR recently proposed a framework distinguishing difficult-to-manage from treatment-refractory psoriatic arthritis. This cohort study applied registry-based components inspired by that framework across five Nordic biologics registries, following 14,362 patients who started a first biologic or targeted synthetic DMARD between 1999 and 2020, with median follow-up of 6.3 years.
Multiple discontinuations were common: 36% stopped at least two such drugs, 18% at least three and 10% at least four. But applying the full set of components — discontinuation for inefficacy or side effects, across different mechanisms of action, with problematic patient-reported symptoms and objectively persistent disease activity — reduced the difficult-to-manage prevalence to 2-3%, and treatment-refractory prevalence to 1.2% or less. Female sex, depression and opioid use all became more common as the number of discontinuations rose.
The gap between 36% and 2% is the finding. Most patients cycling through drugs are not refractory in any biological sense; they are switching for intolerance, for symptoms without objective inflammation, or for reasons that objective criteria do not capture. That distinction matters because it points to different actions — a patient with persistent symptoms and normal inflammatory markers, depression and opioid use needs something other than another biologic. The authors are clear this retrospective design could not test the EULAR definitions themselves.
- 36% discontinued at least two b/tsDMARDs; only 2% were difficult-to-manage
- Treatment-refractory prevalence 1.2% or lower
- Depression, opioid use and female sex rose with number of discontinuations
- Registry design could not formally test the EULAR definitions
The statistics, in plain English
The successive narrowing from 36% to 2% happens because each added criterion — inefficacy as the reason, different mechanisms of action, patient-reported burden, objective inflammation — filters out a different group. That is a demonstration of how much a prevalence figure depends on definition rather than on biology. The association with depression and opioid use is observational and cannot say which came first, but it identifies a group in whom another drug switch is unlikely to be the answer.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for rheumatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free